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Abstract. In the context of time-series forecasting, we propose a LSTM-
based recurrent neural network architecture and loss function that en-
hance the stability of the predictions. In particular, the loss function
penalizes the model, not only on the prediction error (mean-squared er-
ror), but also on the predicted variation error.
We apply this idea to the prediction of future glucose values in diabetes,
which is a delicate task as unstable predictions can leave the patient in
doubt and make him/her take the wrong action, threatening his/her life.
The study is conducted on type 1 and type 2 diabetic people, with a
focus on predictions made 30-minutes ahead of time.
First, we confirm the superiority, in the context of glucose prediction,
of the LSTM model by comparing it to other state-of-the-art models
(Extreme Learning Machine, Gaussian Process regressor, Support Vector
Regressor).
Then, we show the importance of making stable predictions by smoothing
the predictions made by the models, resulting in an overall improvement
of the clinical acceptability of the models at the cost in a slight loss in
prediction accuracy.
Finally, we show that the proposed approach, outperforms all baseline
results. More precisely, it trades a loss of 4.3% in the prediction accu-
racy for an improvement of the clinical acceptability of 27.1%. When
compared to the moving average post-processing method, we show that
the trade-off is more efficient with our approach.
Keywords: Glucose Prediction · Recurrent Neural Network · Loss Func-
tion · Stability · Clinical Acceptability
1 Introduction
With 1.5 milion inputed deaths in 2012, diabetes is one of the leading diseases
in the modern world [26]. Diabetic people, due to the non-production of insulin
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(type 1) or an increased resistance to its action (type 2), have a lot of trouble
managing their blood glucose. In one hand, when their glycemia falls too low
(state of hypoglycemia), they are at risk of short-term complications (e.g., coma,
death). In the other hand, if their glycemia is too high (hyperglycemia), the
complications are long-term (e.g., cardiovascular diseases, blindness).
A lot of efforts are focused towards helping diabetic people in their daily life,
with, for instance, continuous glucose monitoring (CGM) devices (e.g., FreeStyle
Libre [18]), artificial pancreas (e.g., MiniMed 670G [16]), or coaching smartphone
applications for diabetes (e.g., mySugr [20]). Thanks to the advances in the field
of machine learning and the increased availability of data, a lot of researchers
are following the lead of the prediction of future glucose values. The goal is to
build data-driven models that, using the patient’s past information (e.g., glucose
values, carbohydrate intakes, insulin boluses), predict glucose values multiple
minutes ahead of time (we call those models multi-step predictive models).
While a lot of the early work in the glucose prediction field were focused on
the use of autoregressive (AR) models [22], the models that are used nowadays
are more complex. Georga et al. explored the use of Support Vector Regression
(SVR) in predicting glucose up to 120 minutes ahead of time in type 1 diabetes
[9]. Valletta et al. proposed the use of Gaussian Process regressor (GP) to include
a measure of the physical activity of type 1 diabetic patients into the predictive
models [25]. In their work, Daskalaki et al. demonstrated the superiority of feed-
forward neural networks compared to AR models [2]. As for them, Georga et al.
studied the use of Extreme Learning Machine models (ELM) in short-term (PH
of 30 minutes) type 1 diabetes glucose prediction [10]. Finally, recurrent neural
networks (RNN) have shown a lot of interest in the field [27], and in particular
those with long short-term memory (LSTM) units [5, 15,17,24].
However, neural-network-based models, while exhibiting very promising re-
sults, often show instability in the predictions. This comes from the training of
the models that, most of the time, aims at minimizing the mean-squared error
(MSE) loss function. It makes the model focus on getting a good point-accuracy,
without questioning the coherence of consecutive predictions.
The stability of the predictions is very important in predicting future glu-
cose values. Predicting towards the wrong direction or with consecutive inconsis-
tent directions can make the diabetic patient take the wrong action, potentially
threatening his/her life. This is why the accuracy of the predicted glucose vari-
ations is taken into account when assessing the clinical acceptability of glucose
predictive models, with, for instance, the widely-used Continuous Glucose-Error
Grid Analysis (CG-EGA) [19]. We identified that this issue is not specific to the
field of glucose prediction and can be extended to other multi-step forecasting
applications, such as stock market prediction [6] or flood levels forecasting [1].
In this paper, to enhance the stability of the predictions, we propose a new
LSTM-based RNN architecture and loss function. We demonstrate the usefulness
of the idea by applying it to the challenging task of predicting future glucose
values of diabetic patients which directly benefits from an increased stability.
We can summarize our contributions as follows:
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1. We propose a new loss function that penalizes the model simultaneously
during its training, not only on the classical MSE, but also on the predicted
variation error. To be able to compute the penalty, we propose to use the
loss function in a two-output LSTM-based RNN architecture. We validate
the proposed approach by comparing it to four other state-of-the-art models.
2. We demonstrate the importance of making stable predictions in the context
of glucose predictions as accurate but unstable predictions lead the models
to have a bad clinical acceptability.
3. We confirm the overall usefullness of using LSTM-based RNN in predicting
future glucose values by comparing it to other state-of-the-art models. In
particular, the LSTM model shows more clinical acceptable results.
4. We have conducted the study on two different datasets, one with type 1 and
one with type 2 diabetic patients. This is worth mentioning as glucose predic-
tion studies are very rarely done on type 2 diabetes (although it represents
around 90% of the whole diabetic population).
5. Finally, we have made all the source code and a standalone implementation
of the CG-EGA available in Github.
The rest of the paper is organized as follows. First, we introduce the proposed
architecture and loss function. Then, we present its application to the prediction
of future glucose values. Finally, we provide the reader with the results and
takeaways from the experiments.
2 Prediction-Coherent LSTM-based Recurrent Neural
Network
2.1 Presentation of the Model
In multi-step time-series forecasting, at time t, the model takes a set of features
X to predict the future value of the time-series y at a prediction horizon PH:
yˆt+PH . Most of the time, the input features X comprises the past H known
values of the time-series y as well as other time-related features.
RNN, and in particular those based on LSTM cells, are neural networks that
are particularly suited for time-series forecasting as they include the temporal
component of the features and the predictions into their architecture [13]. Such
models are usually trained with the MSE loss function (see Equation 1) which
estimates the mean accuracy of the predictions.
MSE(y, yˆ) =
1
n
n∑
i=1
(yi − yˆi)2 (1)
However, using the MSE does not incentivize the model to make successive
predictions that are coherent with their respective true values. More formally,
we can call two consecutive predictions, yˆt+PH−1 and yˆt+PH , coherent with the
true values when the predicted variation from one to the other, ∆yˆt+PH , reflect
the true variation of the time-series ∆yt+PH .
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To enhance to coherence of consecutive predictions, we propose the idea of
using a two-output LSTM that takes advantage of its architecture to penalize
incoherent successive predictions during its training. We call this neural network
a Prediction-Coherent LSTM-based recurrent neural network (pcLSTM).
Two-output LSTM. The two-output LSTM is a standard LSTM unrolled H
times and that outputs the predictions of the last two steps (see Figure 1).
yˆt+PH−1 yˆt+PH
NN ... NN NN
Xt−H Xt−1 Xt
Fig. 1: two-output LSTM which has been unrolled H times. Xt are the input features
at time t and yˆt+PH is the forecast of the time-series y at a time t + PH.
Variations Penalized Loss Function. To enhance the coherence between two
consecutive predictions, we propose to penalize the network on the error of the
predicted variation. We define the cMSE (see Equation 2), which is the weighted
sum of the MSE of the predictions and the MSE of the predicted variations. We
call the parameter c the coherence factor. It represents the relative importance
of the variation-based penalty compared to the accuracy of the predictions.
cMSE(y, yˆ) = MSE(y, yˆ) + c ·MSE(∆y,∆yˆ)
=
1
n
n∑
i=1
(yi − yˆi)2 + c · (∆yi −∆yˆi)2
(2)
The coherence factor c is a problem-dependent parameter that has to be
optimized depending on the relative importance of having coherent or stable
predictions versus having accurate predictions.
We note that, if the coherence factor, c, is set to 0, the cMSE becomes the
MSE and the model then behaves like a standard one-output LSTM model.
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3 Methods
In this section, we go through the experimental details of the study, and, in
particular, the data we used, the preprocessing steps we followed, the models we
implemented, and the evaluation metrics we used.
We made the source code used in this study available in the pcLSTM Github
repository [4].
3.1 Experimental Data
Our data come from two distinct datasets: the Ohio T1DM dataset and the
IDIAB dataset accounting for 6 type 1 and 5 type 2 diabetic patients respectively.
Ohio Dataset. First published for the Blood Glucose Level Prediction Chal-
lenge in 2018, the OhioT1DM Dataset comprises data from six type 1 diabetic
people who were monitored during 8 weeks [14]. For the sake of simplicity and
the uniformity with the IDIAB dataset, we restrict the dataset to the glucose
readings (in mg/dL), the daily insulin boluses (in units) and the meal informa-
tion (in g of CHO).
IDIAB Dataset. For this study, we conducted a data collection on the type
2 diabetic population. The data collection and the use of the data in this study
has been approved by the french ethical committee “Comite´s de protection des
personnes” (ID RCB 2018-A00312-53).
Five people with type 2 diabetes (4F/1M, age 58.8 ± 8.28 years old, BMI
30.76 ± 5.14 kg/m2, HbA1c 6.8 ± 0.71 %), have been monitored for 31.8 ± 1.17
days in free-living conditions. The patients were equipped with FreeStyle Libre
(FSL) CGM devices (Abbott Diabetes Care) [18], which were recording their
glucose levels (in mg/dL), and with the mySugr (mySugr GmbH) coaching app
for diabetes [20], in which the patient logged his/her food intakes (in g of CHO)
and insulin boluses (in units).
3.2 Preprocessing.
The goal of the preprocessing part is to uniformize the two datasets and prepare
them for the training and testing of the models.
Data Cleaning. To balance the training and the testing sets regarding the
distribution of the samples on the daily timeline, we have chosen to remove
incomplete days from the datasets. As a result, for every patient, we ended up
with an average of 38.5 (± 4.82) and 29.4 (± 1.62) days worth of data for the
Ohio and IDIAB datasets respectively.
We noticed that several glucose readings in the IDIAB dataset were erroneous
(characterized by high amplitude spikes). As this is not particularly surprising
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(a study by Fokkert et al. reported that only 85.5% of the FSL readings were
within ±20% of the reference sensor values [7]), we removed them to prevent
them from disturbing the training of the model.
Resampling & Interpolation. To synchronize the data between them, we
have resampled both datasets to get a sample every 5 minutes. During the re-
sampling process, glucose values have been averaged, insulin boluses and CHO
intakes have been summed up.
To make up for the introduced missing glucose values in the IDIAB dataset
(which has one reading every 15 minutes, instead of 5), we interpolated the
glucose signals as it has already been done in the context of glucose prediction
[23]. In particular, we used a piecewise cubic hermite interpolating polynomial
(PCHIP) [8] to avoid oscillations in the interpolated signal (which occurred with
a single polynomial interpolation) and to preserve the monotonicity of the fitted
signal (which was an issue with a spline interpolation) [12].
Datasets Splitting. To ready up the datasets for the training and testing
of the models, we have to create the training, validation and testing sets. The
splitting of the data has been done on full days of data to ensure an uniform
distribution of the daily sequences across the datasets. We split the data into
training, validation and testing sets following a 50%/25%/25% distribution.
Input Scaling. Lastly, the training sets data have been standardized (zero-
mean and unit-variance). The same transformation has then been applied to the
validation and testing sets.
3.3 Models
In this study, we compare the proposed approach (pcLSTM) to four other state-
of-the-art models, namely an Extreme Learning Machine neural network (ELM),
a Gaussian Process regressor (GP), a LSTM recurrent neural network (LSTM),
and a Support Vector Regression model (SVR).
Every model is personalized to the patient. To be able to model long-term
dependencies, every model takes the past 3 hours of glucose, insulin, and CHO
values as input. The hyperparameters of every model have been tuned on the
validation sets by grid search.
ELM. The ELM architecture has 105 neurons in its single hidden layer. To
reduce the impact of overfitting, we applied a L2 penalty (500) to the weights.
GP. The GP model has been implemented with a dot-product kernel. The dot-
product has been chosen instead of a traditional radial basis function kernel as
it has been shown to perform better in the context of glucose prediction [5]. The
inhomogeneity parameter of the kernel has been set to 10−8. To ease the fitting
of the model, white noise (value of 10−2) has been added to the observations.
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LSTM. The LSTM model is made of a single hidden layer of 128 LSTM units. It
has been trained to minimize the MSE loss function using the Adam optimizer
with batches of 10 samples and a learning rate of 5 × 10−3. To prevent the
overfitting of the network to the training data, we added a L2 penalty (10−4)
and used the early stopping methodology.
pcLSTM. The pcLSTM recurrent neural network shares the same characteris-
tics with the LSTM model. The only difference is its two-output architecture and
its associated cMSE loss function (see Section 2). In particular, the coherence
factor has been optimized through grid search to ensure a good trade-off between
the accuracy of the predictions and the accuracy of the predicted variations. We
settled down with a coherence factor of 2.
SVR. The SVR model has been implemented with a radial basis function (RBF)
kernel. The coefficient of the kernel has been set to 5 × 10−4. The wideness of
the no-penalty tube has been set to 0.1 and the penalty itself has been set to 50.
3.4 Post-processing
By using the cMSE loss function, we incentivize the model to make consecutive
predictions reflecting the actual glucose rate of change. In a way, it can be viewed
as a smoothing effect integrated to the training of the model.
Some post-processing time-series smoothing techniques exist, such as the
exponential smoothing or the moving average smoothing [21]. The latter, yielding
a better trade-off between the accuracy of the predictions and the accuracy of
the predicted variations, has been used with a window of the last 3 predictions.
3.5 Evaluation Metrics
In this study, three evaluation metrics have been used: the Root-Mean-Squared
prediction Error (RMSE), the Root-Mean-Squared predicted variation Error
(dRMSE), and the Continuous Glucose-Error Grid Analysis (CG-EGA) mea-
suring the clinical acceptability of the predictions.
RMSE. The RMSE is the most used metric in the world of glucose prediction
as it measures the overall accuracy of the predictions [19].
dRMSE. We call the dRMSE the RMSE applied to the difference between two
consecutive predictions. Therefore, it measures the accuracy of the predicted
variations and can be used to estimate the impact of the variation-based penalty
in the cMSE loss function.
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CG-EGA. The CG-EGA provides a measure of the clinical acceptability of
the predictions [19]. Indeed, predictions, depending on the current state of the
patient’s glycemia (hypoglycemia, euglycemia4, or hyperglycemia), can be more
or less dangerous, which is not taken into account in metrics such as the RMSE.
Technically, the CG-EGA is made of two grids: the Point-Error Grid Analy-
sis (P-EGA) and the Rate-Error Grid Analysis (R-EGA). Whereas the P-EGA
provides an acceptability score (from A to E) to the glucose predictions, the
R-EGA gives each prediction a score (also from A to E) based on the variation
from the previous prediction to the current one [11]. The CG-EGA combines
both grids and gives, for every prediction, in its simplified representation, a
clinical acceptability category: accurate prediction (AP), benign error (BE), or
erroneous prediction (EP). For a prediction to be categorized as an AP, it needs
to have a score of A or B in both the P-EGA and the R-EGA.
We published the source code of the CG-EGA implementation in Github [3].
4 Results and Discussion
The results of the models, presented with and without the moving average
smoothing technique discussed in Section 3.4, are reported in Table 1. Figure
2 gives a graphical representation of the effect of the proposed approach on
the predictions. A detailed graphical clinical acceptability classification of the
predictions is given by Figure 3.
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Fig. 2: Glucose predictions of the unsmoothed LSTM and pcLSTM against the ground
truth, for a given day of one of the patients.
4 The euglycemia region is the region between hypoglycemia and hyperglycemia.
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Table 1: Performances of the ELM, GP, LSTM, pcLSTM, and SVR models, evaluated
at a prediction horizon of 30 minutes with and without the smoothing of the predictions
(mean ± standard deviation, averaged on the subjects from both datasets).
Model RMSE dRMSE
CG-EGA
AP BE EP
Without smoothing
ELM 25.54 ± 5.02 1.90 ± 0.45 79.34 ± 7.53 14.92 ± 5.50 5.74 ± 2.33
GP 18.92 ± 4.56 2.21 ± 0.44 81.70 ± 6.21 13.88 ± 4.09 4.41 ± 2.28
LSTM 19.48 ± 4.42 1.95 ± 0.40 82.98 ± 5.65 12.42 ± 3.73 4.60 ± 2.06
pcLSTM 20.32 ± 4.56 1.47 ± 0.31 87.60 ± 4.74 8.76 ± 3.23 4.01 ± 1.84
SVR 20.08 ± 4.24 1.74 ± 0.44 83.92 ± 6.10 11.75 ± 4.24 4.32 ± 2.01
With smoothing
ELM 26.64 ± 5.17 1.42 ± 0.31 86.13 ± 5.26 9.31 ± 3.89 4.57 ± 1.79
GP 20.42 ± 4.70 1.48 ± 0.31 87.17 ± 4.38 9.08 ± 3.03 3.74 ± 1.65
LSTM 21.21 ± 4.63 1.41 ± 0.30 87.51 ± 4.45 8.60 ± 3.15 3.89 ± 1.60
pcLSTM 22.42 ± 4.85 1.29 ± 0.28 88.82 ± 4.43 7.36 ± 3.18 3.81 ± 1.68
SVR 21.81 ± 4.43 1.42 ± 0.32 87.38 ± 4.78 8.79 ± 3.37 3.83 ± 1.63
First, when looking at the unsmoothed baseline results, apart from the ELM
model that has overall the worse performances (excluding it from the follow-
ing analysis), we can see that the models have different strengths and weak-
nesses. Whereas the GP model stands out as being the most point-accurate
model (RMSE), it is also the most unstable model (dRMSE). This makes it the
least clinically acceptable model of the remaining three, having the lowest AP
and the highest EP rates. On the other hand, the SVR model has the worse
RMSE, the best dRMSE, and the best AP and EP rates, making it the most
clinically acceptable baseline model. Finally, the LSTM model displays compet-
itive results with respect to the GP and SVR models, which validates the use of
the LSTM model in the context of glucose prediction.
When looking at the unsmoothed performances of the pcLSTM model, we can
see that, compared to the LSTM model, its RMSE is slightly worse (+4.3%),
its dRMSE drastically improved (−24.6%) and so is its clinical acceptability
(+27.1% and −12.8% for the room for improvement in the AP and EP rates
respectively). This shows the importance of focusing on the coherence of succes-
sive predictions as the increased accuracy in predicted variations (dRMSE) is
the main contributor to the increased clinical acceptability.
The results of the models with smoothed predictions show us the general ben-
efit of improving the stability of the predictions to make them more clinically
acceptable. Even though all the models see their clinical acceptability improved,
the improvement varies from model to model: the models with the highest insta-
bility benefit from the smoothing the most. In average, the improvement due to
the smoothing applied on the baseline models (still excluding the ELM model) is
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Fig. 3: P-EGA (left) and R-EGA (right) for LSTM (top) and pcLSTM (bottom) mod-
els for a patient during a given day. The CG-EGA classification (AP, BE, or EP) is
computed by combining both P and R-EGA ranks.
of +8.5%, −24.3%, +26.0%, and −14.14% in RMSE, dRMSE, AP and EP rates
respectively. Those results show us that the trade-off made by the pcLSTM is
much more efficient (+8.5% against +4.3% in RMSE for overall the same im-
provement in the other metrics).
5 Conclusion
In this paper, we have presented a new loss function for recurrent neural networks
which, by penalizing the model on the predicted variation errors in addition to
the prediction errors, helps the network making more stable predictions.
We apply the proposed model to the prediction of future glucose values in di-
abetes. First, we validate the use of recurrent neural networks (in particular with
LSTM units) by showing that our baseline LSTM model is competitive when
compared to other state-of-the-art models. Then, we demonstrate the impor-
tance of the proposed approach as it greatly improves the clinical acceptability
of the predictions. Lastly, we compare the proposed approach to another smooth-
ing technique. While the effect on the clinical acceptability is the same, the loss
in the accuracy of the prediction is higher, making our proposed approach more
efficient.
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The tuning of the coherence factor in the cMSE loss function is of paramount
importance for the proposed approach. The desired stability is application de-
pendant and must, in the case of glucose prediction, be assessed by practitioners.
In the future we plan on improving the loss function further by adding penalties
directly tied to the CG-EGA (e.g., penalizing the model when the prediction is
an EP).
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